WO2008121963A3 - Compositions and methods for gene silencing - Google Patents

Compositions and methods for gene silencing Download PDF

Info

Publication number
WO2008121963A3
WO2008121963A3 PCT/US2008/058907 US2008058907W WO2008121963A3 WO 2008121963 A3 WO2008121963 A3 WO 2008121963A3 US 2008058907 W US2008058907 W US 2008058907W WO 2008121963 A3 WO2008121963 A3 WO 2008121963A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
gene silencing
silencing
gene
Prior art date
Application number
PCT/US2008/058907
Other languages
French (fr)
Other versions
WO2008121963A2 (en
Inventor
Rafal Goraczniak
Samuel I Gunderson
Original Assignee
Univ Rutgers
Rafal Goraczniak
Samuel I Gunderson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers, Rafal Goraczniak, Samuel I Gunderson filed Critical Univ Rutgers
Priority to EP08733027A priority Critical patent/EP2142672B1/en
Publication of WO2008121963A2 publication Critical patent/WO2008121963A2/en
Publication of WO2008121963A3 publication Critical patent/WO2008121963A3/en
Priority to US12/570,389 priority patent/US8907075B2/en
Priority to US13/082,865 priority patent/US8343941B2/en
Priority to US13/687,644 priority patent/US9078823B2/en
Priority to US14/529,923 priority patent/US9441221B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions and methods for modulating the expression of a protein of interest are provided.
PCT/US2008/058907 2007-03-30 2008-03-31 Compositions and methods for gene silencing WO2008121963A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP08733027A EP2142672B1 (en) 2007-03-30 2008-03-31 Compositions and methods for gene silencing
US12/570,389 US8907075B2 (en) 2007-03-30 2009-09-30 Compositions and methods for gene silencing
US13/082,865 US8343941B2 (en) 2007-03-30 2011-04-08 Compositions and methods for gene silencing
US13/687,644 US9078823B2 (en) 2007-03-30 2012-11-28 Compositions and methods for gene silencing
US14/529,923 US9441221B2 (en) 2007-03-30 2014-10-31 Compositions and methods for gene silencing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92103207P 2007-03-30 2007-03-30
US60/921,032 2007-03-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/570,389 Continuation-In-Part US8907075B2 (en) 2007-03-30 2009-09-30 Compositions and methods for gene silencing

Publications (2)

Publication Number Publication Date
WO2008121963A2 WO2008121963A2 (en) 2008-10-09
WO2008121963A3 true WO2008121963A3 (en) 2008-11-20

Family

ID=39808886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/058907 WO2008121963A2 (en) 2007-03-30 2008-03-31 Compositions and methods for gene silencing

Country Status (2)

Country Link
EP (1) EP2142672B1 (en)
WO (1) WO2008121963A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130260460A1 (en) 2010-04-22 2013-10-03 Isis Pharmaceuticals Inc Conformationally restricted dinucleotide monomers and oligonucleotides
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US11142762B2 (en) 2012-07-05 2021-10-12 The Trustees Of The University Of Pennsylvania U1 snRNP regulates gene expression and modulates oncogenicity
CA3205381A1 (en) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
KR20180117630A (en) * 2016-02-02 2018-10-29 메이라지티엑스 유케이 Ii 리미티드 Regulation of Gene Expression by Utter-Modulated Polyadenylation
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082149A1 (en) * 1997-07-28 2003-05-01 Cummings & Lockwood Inhibition of a target messenger rna with a modified u1 small nuclear rna
US20030143732A1 (en) * 2001-04-05 2003-07-31 Kathy Fosnaugh RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20020253A1 (en) * 2002-05-08 2003-11-10 Univ Roma SNRNA CHEMICAL MOLECULES WITH ANTISENSE SEQUENCES FOR SPLICING JUNCTIONS OF THE DYSTROPHINE GENE AND THERAPEUTIC APPLICATIONS.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082149A1 (en) * 1997-07-28 2003-05-01 Cummings & Lockwood Inhibition of a target messenger rna with a modified u1 small nuclear rna
US20030143732A1 (en) * 2001-04-05 2003-07-31 Kathy Fosnaugh RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2142672A4 *

Also Published As

Publication number Publication date
EP2142672B1 (en) 2012-09-05
EP2142672A2 (en) 2010-01-13
WO2008121963A2 (en) 2008-10-09
EP2142672A4 (en) 2011-02-16

Similar Documents

Publication Publication Date Title
WO2008052187A3 (en) Antibodies and immunoconjugates and uses therefor
WO2007130697A8 (en) Anti-ephb4 antibodies and methods using same
WO2008133938A3 (en) Targeted integration into the ppp1r12c locus
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2008157356A3 (en) Antibody formulations
WO2007025247A3 (en) Transglutaminase inhibitors and methods of use thereof
WO2008002893A8 (en) Anti-amyloid antibodies, compositions, methods and uses
WO2009060418A3 (en) Transgenic plants and modulators for improved stress tolerance
WO2007050795A3 (en) Transglutaminase inhibitors and methods of use thereof
WO2009094577A3 (en) Mesophasic forms of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
GB0602992D0 (en) Methods, genes and proteins
ZA200807714B (en) Gene disruptions, compositions and methods relating thereto
WO2009111586A3 (en) Autonomous in vitro evolution
WO2008013990A3 (en) Processes for the synthesis of o-desmethylvenlafaxine
WO2007127506A3 (en) Anti-ephrinb2 antibodies and methods using same
WO2008085900A3 (en) Methods for generating novel stabilized proteins
WO2007087601A8 (en) Modulating plant protein levels
WO2008121963A3 (en) Compositions and methods for gene silencing
ZA200808498B (en) Novel gene disruptions,compositions and methods relating thereto
AU2006335053A8 (en) Novel gene disruptions, compositions and methods relating thereto
EP2015782A4 (en) Compositions and methods for modulating gene expression
EP2019594A4 (en) Extract of r. miehei
WO2011050188A8 (en) Anti-hepsin antibodies and methods using same
WO2007095405A3 (en) Modifying data
WO2008147426A3 (en) Methods and compositions for immunomodulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08733027

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008733027

Country of ref document: EP